Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mebarki

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Blood Advances|June 21, 2022
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphomaAlexis Cuffel, Vincent Allain, Lionel Faivre, et al.
Nature Communications|December 16, 2015
Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapyP Rocheteau, L Chatre, D Briand, et al.
Cancers|February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
Haematologica|June 9, 2022
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cellsJean Galtier, Laetitia Vercellino, Loic Chartier, et al.
British Journal of Haematology|May 12, 2024
Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemiaMarie Emilie Dourthe, Karima Yakouben, Audrey David, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Critical Care (London, England)|February 22, 2022
Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trialAntoine Monsel, Caroline Hauw-Berlemont, Miryam Mebarki, et al.
Stem Cell Research & Therapy|April 18, 2024
Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of lifeAlexandre Sitbon, Caroline Hauw-Berlemont, Miryam Mebarki, et al.
Infectious Disease Modelling|March 6, 2024
Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop reportMarta C Nunes, Edward Thommes, Holger Fröhlich, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Blood Advances|June 21, 2022
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphomaAlexis Cuffel, Vincent Allain, Lionel Faivre, et al.
Nature Communications|December 16, 2015
Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapyP Rocheteau, L Chatre, D Briand, et al.
Cancers|February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
Haematologica|June 9, 2022
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cellsJean Galtier, Laetitia Vercellino, Loic Chartier, et al.
British Journal of Haematology|May 12, 2024
Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemiaMarie Emilie Dourthe, Karima Yakouben, Audrey David, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Critical Care (London, England)|February 22, 2022
Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trialAntoine Monsel, Caroline Hauw-Berlemont, Miryam Mebarki, et al.
Stem Cell Research & Therapy|April 18, 2024
Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of lifeAlexandre Sitbon, Caroline Hauw-Berlemont, Miryam Mebarki, et al.
Infectious Disease Modelling|March 6, 2024
Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop reportMarta C Nunes, Edward Thommes, Holger Fröhlich, et al.
Pageof 13